14075
post-template-default,single,single-post,postid-14075,single-format-standard,strata-core-1.0.1,strata-child-theme-ver-1.0.0,strata-theme-ver-3.0.3,ajax_fade,page_not_loaded,wpb-js-composer js-comp-ver-6.0.3,vc_responsive

New study reveals Oxford coronavirus vaccine produces strong immune response

15:51 23 July in Life Sciences & Healthcare, News, Oxfordshire

Oxford University’s Jenner Institute and Oxford Vaccine Group have taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.

The results of the Phase I/II trial indicate no early safety concerns and induces strong immune responses in both parts of the immune system.

The vaccine provoked a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus), and an antibody response within 28 days (antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted).

“We saw the strongest immune response in the 10 participants who received two doses of the vaccine, indicating that this might be a good strategy for vaccination.”

Professor Pollard, Oxford Vaccine Group

 

The University of Oxford is working with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the Covid-19 vaccine, with plans for clinical development and production of the Oxford vaccine progressing globally. The project has been further spurred by £84 million of Government funding to help accelerate the vaccine’s development

“We are encouraged by the Phase I/II interim data showing AZD1222 was capable of generating a rapid antibody and T-cell response against SARS-CoV-2. While there is more work to be done, today’s data increases our confidence that the vaccine will work and allows us to continue our plans to manufacture the vaccine at scale for broad and equitable access around the world.”

Mene Pangalos, Executive Vice President of BioPharmaceuticals Research and Development at AstraZeneca.

 

“Today’s results are extremely encouraging, taking us one step closer to finding a successful vaccine to protect millions in the UK and across the world. Backed by £84 million Government investment for the vaccine’s development and manufacture, the agility and speed with which the University of Oxford have been working is outstanding. I am very proud of what they have achieved so far.”

The Rt Hon, Alok Sharma MP, Secretary of State for Business, Energy and Industrial Strategy

 

Read the full article HERE.